Dako enters new collaboration on targeted therapies for non-small cell lung cancer
Dako possesses substantial technical knowledge regarding the utility of immunochemistry for use in characterization of EGFR protein expression in tumor cells and markets the product, EGFR pharmDx(TM), to assess clinical colon cancer tissue specimens for the presence of the EGFR protein, thereby aiding the physician in choosing appropriate therapy. Genentech, OSI and Roche have access to substantial proprietary and confidential technical and scientific information regarding their product Tarceva and were seeking a capable diagnostic collaborator.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.